RSV can have serious respiratory consequences.
Help protect your baby from lung disease caused by RSV with ABRYSVO.
More than
75%
Help protect your baby from RSV from their first breath with ABRYSVO
ABRYSVO is a vaccine developed by Pfizer that can help prevent disease of the lower respiratory tract (lungs) caused by RSV (respiratory syncytial virus).
ABRYSVO is given to pregnant individuals in the third trimester (from 32 through 36 weeks of their pregnancy) to help protect their babies when they are most vulnerable—from birth through 6 months of age.
As with any vaccine, ABRYSVO will not protect 100% of those who receive it. ABRYSVO is not a treatment for RSV infection or its complications.
More than 3,600
pregnant participants received ABRYSVO during its Phase 3 trial
Among the pregnant participants, the most common side effects following ABRYSVO were pain where the injection was given, headache, and muscle pain.
No side effects were reported in babies born to vaccinated mothers.
Like all vaccines, ABRYSVO can cause side effects, although not everyone experiences them.
ABRYSVO is given from 32 through 36 weeks of pregnancy
Talk to your pregnancy care provider about helping to protect your baby from RSV with ABRYSVO.
Need a reminder? We’ve got you covered.
*Based on US data from 2006 to 2011.
ABRYSVO is a vaccine to help prevent disease of the lower respiratory tract (lungs) caused by RSV (respiratory syncytial virus). ABRYSVO is given to pregnant individuals (from 32 through 36 weeks’ gestation) to protect their infants from birth through 6 months of age, and individuals 60 years of age and older. As with any vaccine, ABRYSVO will not protect 100% of those who receive it. ABRYSVO is not a treatment for RSV infection or its complications. Like all vaccines, ABRYSVO can cause side effects, although not everybody gets them.
For more information, please consult the Product Monograph or call 1-800-463-6001.